– Leading expert in translational medicine and neuroscience leading Dopavision’s research activities

Berlin, Germany, March 21, 2023 — dopavision, a clinical-stage company pioneering the development of digitally delivered light-based therapeutics, today announced the appointment of Prof. Dr. Jens Ellrich as Chief Scientific Officer. Jens Ellrich brings a wealth of scientific knowledge and extensive experience in digital therapeutics, including new product development. He will oversee Dopavision’s ambitious research and development activities for the company’s flagship product, myopiaX^®, Dopavision’s lead digital therapeutic to control myopia in children. The first human clinical trial of MyopiaX^® runs all over Europe.

Jens Ellrich, MD, PhD is a translational medicine professional with a strong background and track record in basic and clinical neuroscience, including various eye diseases and the development of digital therapeutics. He was a full professor at RWTH Aachen University and Aalborg University and is the author of more than 85 peer-reviewed publications. Jens entered the medical device industry in 2010 and has held positions including Chief Medical Officer for neurotechnology companies Cerbomed, Sapiens, EBS Technologies and WISE. In addition to his managerial roles in the healthcare industry, he is adjunct professor of neuroscience at the medical faculty of the University of Erlangen-Nuremberg and a member of the editorial boards of the scientific journals European Journal of Pain and Bioelectronic Medicine.

“We warmly welcome Jens to our leadership team,” said Mark Wuttke, CEO of Dopavision. “He brings a wealth of scientific knowledge and significant experience in developing digital therapeutics and shares our commitment to strong scientific programs. His deep skills and extensive network will be of great help in the successful execution of our myopia control program and as we continue to grow our pipeline.”

“I’m happy to be part of it…